Define the NHS problem
Test whether fragmented peptide information creates avoidable search time, inconsistent status interpretation or governance risk for medicines and clinical teams.
PATHWAY, NOT AN APPROVAL BADGE
From an NHS problem to evidence, assurance and adoption.
The NHS Innovation Service is the front door for support. It does not itself approve or procure the product, and a submission does not imply NHS adoption.
Submit an innovation record
Describe the product, intended users, pathway, value proposition, current evidence, testing, standards, revenue model and exact support requested.
Confirm classification and assurance
Seek direction on ESF tier, MHRA software status, DTAC, DCB0129, DSPT and the minimum evidence needed for a safe pilot.
Run a bounded UK evaluation
Use predefined questions, a comparison method and explicit measures for time, correctness, source verification, usability and unintended consequences.
Choose the route from evidence
Use results to decide whether local procurement, a Health Innovation Network route, NICE Advice or future NICE HealthTech evaluation is proportionate.
PROPOSED NHS USE CASE
Professional peptide status and exposure intelligence.
When a clinician, pharmacist or medicines team encounters an authorised peptide medicine, a late-stage investigational therapy or a substance already circulating in private or research markets, Peptide Intelligence provides a source-linked view of what the product is, which authority has done what, what evidence supports the claim and where uncertainty remains.
PILOT OUTCOMES
Claims we will measure, not assume.
Primary outcome: time to reach and verify a correct regulatory and access answer. Secondary outcomes: answer completeness, source verification success, user confidence, workflow fit, repeat use and identified safety or governance gaps.